DA-R-EPOCH PROTOKOLÜ
Kaynaklar:
1-Yuan, P., G. J. Grimes, S. E. Shankman, et al. 2001. "Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide phosphate in 0.9% sodium chloride injection." Am J Health Syst Pharm 58(7):594-598.
2- Wolfe, J. L., L. A. Thoma, C. Du, et al. 1999. "Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide in 0. 9% sodium chloride injection." Am J Health Syst Pharm 56(10):985-989.
3-Bartlett, N. L., W. H. Wilson, S. H. Jung, et al. 2019. "Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303." J Clin Oncol 37(21):1790-1799.
4-Wilson, W. H., M. L. Grossbard, S. Pittaluga, et al. 2002. "Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy." Blood 99(8):2685-2693.
5- Wilson, W. H., S. H. Jung, P. Porcu, et al. 2012. "A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype." Haematologica 97(5):758-765.
6- Garcia-Suarez, J., E. Flores, M. Callejas, et al. 2013. "Two-weekly dose-adjusted (DA)-EPOCH-like chemotherapy with high-dose dexamethasone plus rituximab (DA-EDOCH14-R) in poor-prognostic untreated diffuse large B-cell lymphoma." Br J Haematol 160(4):510-514.
7-Little, R. F., S. Pittaluga, N. Grant, et al. 2003. "Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology." Blood 101(12):4653-4659.
8- Jermann, M., L. M. Jost, Ch Taverna, et al. 2004. "Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study." Ann Oncol 15(3):511-516.
9- Garcia-Suarez, J., H. Banas, I. Arribas, et al. 2007. "Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study." Br J Haematol 136(2):276-285.
10-Purroy, N., J. Bergua, L. Gallur, et al. 2015. "Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group." Br J Haematol 169(2):188-198.
11- Dunleavy, K., S. Pittaluga, L. S. Maeda, et al. 2013. "Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma." N Engl J Med 368(15):1408-1416.
12- Wilson, W., J. Sin-Ho, B. Pitcher, et al. 2016. “Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303.” Blood 128(22): 469.
13- Petrich, A. M., M. Gandhi, B. Jovanovic, et al. 2014. "Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis." Blood 124(15):2354-2361.
14-Oki, Y., M. Noorani, P. Lin, et al. 2014. "Double hit lymphoma: the MD Anderson Cancer Center clinical experience." Br J Haematol 166(6):891-901.
15- Friedberg, J. W. 2017. "How I treat double-hit lymphoma." Blood 130(5):590-596.
16-Dunleavy, K., M. A. Fanale, J. S. Abramson, et al. 2018. "Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study." Lancet Haematol 5(12):e609-e617.
